Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Sponsor

Cancer Prevention Pharmaceuticals, Inc. (Industry)

Overall Status

Withdrawn

CT.gov ID

NCT01636128

Collaborator

University of Arizona (Other)

Enrollment

Arms

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the effects of 2 drugs (sulindac and Difluoromethylornithine (DFMO)) either alone or in combination on biomarkers found in urine.

Condition or Disease	Intervention/Treatment	Phase
Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms	Drug: difluoromethylornithine Drug: Sulindac	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)

Study Start Date :

Mar 1, 2014

Anticipated Primary Completion Date :

Mar 1, 2016

Anticipated Study Completion Date :

Apr 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sulindac first (Treatment Sequence B) Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO	Drug: difluoromethylornithine 500 mg oral for 14 days, combined with sulindac for 15 days Other Names: DFMO, eflornithine Drug: Sulindac 150 mg oral for 15 days, combined with DFMO for 14 days
Experimental: DFMO first (Treatment Sequence A) DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac	Drug: difluoromethylornithine 500 mg oral for 14 days, combined with sulindac for 15 days Other Names: DFMO, eflornithine Drug: Sulindac 150 mg oral for 15 days, combined with DFMO for 14 days

Arm

Intervention/Treatment

Experimental: Sulindac first (Treatment Sequence B)

Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO

Drug: difluoromethylornithine

500 mg oral for 14 days, combined with sulindac for 15 days

Other Names:

DFMO, eflornithine

Drug: Sulindac

150 mg oral for 15 days, combined with DFMO for 14 days

Experimental: DFMO first (Treatment Sequence A)

DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac

Drug: difluoromethylornithine

500 mg oral for 14 days, combined with sulindac for 15 days

Other Names:

DFMO, eflornithine

Drug: Sulindac

150 mg oral for 15 days, combined with DFMO for 14 days

Outcome Measures

Primary Outcome Measures

Measure intra-subject urine N1-monoacetylspermidine and dcSAM variability during the pre-drug phase [Week 1-Week 2]
Measure initial variability in levels of urinary biomarkers prior to initiation of drug treatment. Three blood draws over the first 14 days will be used to assess baseline variability.
Determine dcSAM content of urine after 14 days of 500mg DFMO daily alone [Week 4]
Measure urinary biomarker dcSAM after 14 days of single agent DFMO. Measure urinary biomarker dcSAM after 14 days of single agent DFMO for treatment arm where DFMO alone is started week 2 (Treatment sequence A).
Determine N1-monoacetylspermidine content of urine after 14 days plus 1 day of 150 mg sulindac alone [Week 4]
Measure urinary biomarker dcSAM after 14 days of single agent sulindac. Measure urinary biomarker dcSAM after 14 days of single agent sulindac for treatment arm where sulindac alone is started week 2 (Treatment sequence B).
Determine dcSAM and N1-monoacetylspermidine content of urine after 14 days of 150 mg sulindac daily combined with DFMO at 500 mg/day [Week 20]
Determine dcSAM content of urine after 14 days of 500mg DFMO daily alone [Week 12]
Measure urinary biomarker dcSAM after 14 days of single agent DFMO for treatment arm where DFMO alone is started week 10 (Treatment sequence B)
Determine N1-monoacetylspermidine content of urine after 14 days plus 1 day of 150 mg sulindac alone [Week 12]
Measure urinary biomarker dcSAM after 14 days of single agent sulindac. Measure urinary biomarker dcSAM after 14 days of single agent sulindac for treatment arm where sulindac alone is stated week 10 (Treatment sequence A).

Secondary Outcome Measures

Determine if 2 weeks is sufficient time for dcSAM levels and N1-monoacetylspermidine content of urine to recover after stopping DFMO and sulindac [Week 22]
Determine the length of time it takes for sulindac or DFMO to induce measurable changes in biomarker content of urine [Week 3-Week 25]
Explore the effect of dietary intake of polyamine measured using the Arizona Food Frequency Questionnaire [Week 1-25]
Quantitate dietary polyamine levels over the course of the study and evaluate the effects on biomarkers evaluated in the primary outcome measures.

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age 40-65 years
Fluent in English
PS 0 ECOG
Must be able to discontinue the use of aspirin, aspirin containing products, and other non-steroidal anti-inflammatory agents for the duration of the study agent administration period
Negative fecal occult blood test
Hemoglobin > 10g/dl, WBC must be >4,000 mm3, platelets must be > 100,000/mm3
Serum creatinine must be < 1.5 m/dl
Serum bilirubin must be < 2.0 mg/dl, AST and ALT must be < 1.5x upper limit of normal range
Female participants must be postmenopausal (at least 1 year since the last menstrual period), surgically sterilized, or willing to use an effective birth control method (e.g., hormonal contraceptive, oral contraceptives, intrauterine device, diaphragm with spermicide, or abstinence) for the duration of the study. Male subjects must use an effective method of birth control throughout the duration of the study and should not impregnate a female.
Females of childbearing potential must have a negative serum pregnancy test prior to the start of study medication.
Able to give signed, written informed consent

Exclusion Criteria:

Requires corticosteroids or nonsteroidal anti-inflammatory agents
Individuals who are immunosuppressed by virtue of medication or disease. This includes participants known to have AIDS, subjects taking oral steroids, and subjects on immunosuppressants/immunomodulators (cyclosporine, chemotherapeutic agents, or biologic therapy)
Current use of phenytoin or sulfonamides
Current or recent (within 3 months) use of coumadin or other systemic anticoagulants.
Frequently, chronic or moderate/severe gastric complaints. Upper gastrointestinal problems requiring prescription or nonprescription medical remedies for symptoms of heartburn, dyspepsia, nausea, or abdominal pain > once per week on average
History of peptic ulcer, occult or gross intestinal bleeding
Known intercurrent illness, including but no limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal disease, liver disease, ongoing or active infection, psychiatric illness, or other situations that would limit compliance or interfere with the ability to comply with the study regimen.
History of bleeding or clotting disorders
Individuals with seizures or history of seizures
History of abnormal wound healing or repair, or conditions that predisposes to the same including diabetes
Unwilling or unable to limit alcohol consumption to 2-3 servings per week during the study period (12oz beer, 1 oz per alcoholic beverage, 6 oz per wine)
Individuals enrolled in or who plan to enroll in a clinical intervention trial. There must be a 30 day period between completing a previous study and enrolling in this study.
Pregnant or lactating women
Prior DFMO exposure
History of allergic reaction (e.g., urticaria, asthma, rhinitis) or gastric intolerance attributed to NSAIDs